Monofer (Ferric Derisomaltose)

Ferric derisomaltose, the active ingredient in Monofer, is an iron preparation presented as an intravenous solution for parenteral use. It is indicated for the treatment of iron deficiency anemia, including in patients with chronic kidney disease and those who cannot tolerate oral iron therapy.

GNH USA supplies Monofer as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Monofer is employed in clinical practice to correct iron deficiency anemia, a condition characterized by insufficient hemoglobin synthesis, by delivering a large dose of iron directly into the bloodstream. - Iron deficiency anemia: restores hemoglobin levels and improves fatigue and related symptoms. - Chronic kidney disease with iron deficiency: repletes iron stores to support anemia management in dialysis patients. - Intolerance to oral iron: provides intravenous iron to achieve rapid correction when oral agents are not tolerated.

Common Side Effects: - Nausea: mild to moderate feeling of stomach upset. - Headache: transient headache occurring during or shortly after infusion. - Infusion‑site reactions: pain, erythema, or swelling at the injection site. - Dizziness: temporary light‑headedness during administration. - Vomiting: occasional upset stomach leading to emesis. - Transient hypotension: brief drop in blood pressure during infusion.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Severe hypotension: marked drop in blood pressure that may cause syncope. - Acute respiratory distress: difficulty breathing or bronchospasm. - Iron overload: excessive iron accumulation with potential organ damage. - Cardiac arrest: rare but life‑threatening cardiac event. - Severe allergic reaction: including angioedema or urticaria.

Monofer should be used with careful clinical assessment and monitoring. - Assess iron status before administration: confirm iron deficiency with ferritin and TSAT values. - Monitor for hypersensitivity: observe the patient during and after infusion for signs of reaction. - Avoid rapid infusion in patients with cardiovascular disease: administer at the recommended rate. - Use caution in active infection: iron may promote bacterial growth. - Pregnancy and lactation: use only if the expected benefit outweighs potential risk. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Monofer may interact with other agents that affect iron metabolism or cardiovascular stability. Major Interactions (Avoid): - Concurrent IV iron products: risk of iron overload. - High‑dose erythropoiesis‑stimulating agents: may increase hypertension risk. - Iron‑chelating antibiotics (e.g., tetracyclines): reduce iron efficacy. Moderate Interactions (Monitor Closely): - Oral iron supplements: may interfere with absorption; separate by at least 4 h. - Vitamin C supplements: can increase iron release; monitor iron parameters. - Anticoagulants: monitor for bleeding if infusion causes hypotension.